

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8283792

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
IMPAX LABORATORIES, LLC	11/14/2023

RECEIVING PARTY DATA

Name:	JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Street Address:	10 S. DEARBORN STREET
City:	CHICAGO
State/Country:	ILLINOIS
Postal Code:	60603

PROPERTY NUMBERS Total: 17

Property Type	Number
Application Number:	12599668
Application Number:	13367230
Application Number:	13711248
Application Number:	13900408
Application Number:	14030792
Application Number:	14030813
Application Number:	14958975
Application Number:	15027654
Application Number:	15092086
Application Number:	15382851
Application Number:	16360936
Application Number:	16573634
Application Number:	16864323
Application Number:	17148320
Application Number:	17372434
Application Number:	17959681
Application Number:	18131715

CORRESPONDENCE DATA

Fax Number: (212)751-4864

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

PATENT

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2129061209
Email: jess.bajada-bartlett@lw.com
Correspondent Name: LATHAM & WATKINS C/O JESSICA BAJADA-BARTLETT
Address Line 1: 1271 AVENUE OF THE AMERICAS
Address Line 4: NEW YORK, NEW YORK 10020

ATTORNEY DOCKET NUMBER:	045494-0508
NAME OF SUBMITTER:	JESSICA BAJADA-BARTLETT
SIGNATURE:	/s/ Jessica Bajada-Bartlett
DATE SIGNED:	11/17/2023

Total Attachments: 10

source=New Patent Security Agreement FINAL [Executed]#page1.tif
source=New Patent Security Agreement FINAL [Executed]#page2.tif
source=New Patent Security Agreement FINAL [Executed]#page3.tif
source=New Patent Security Agreement FINAL [Executed]#page4.tif
source=New Patent Security Agreement FINAL [Executed]#page5.tif
source=New Patent Security Agreement FINAL [Executed]#page6.tif
source=New Patent Security Agreement FINAL [Executed]#page7.tif
source=New Patent Security Agreement FINAL [Executed]#page8.tif
source=New Patent Security Agreement FINAL [Executed]#page9.tif
source=New Patent Security Agreement FINAL [Executed]#page10.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT is dated as of November 14, 2023, by AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company, IMPAX LABORATORIES, LLC, a Delaware limited liability company and GEMINI LABORATORIES, LLC, a Delaware limited liability company (each, individually, a "Grantor" and, collectively, the "Grantors"), in favor of JPMorgan Chase Bank, N.A., in its capacity as administrative agent and collateral agent (in such capacity, the "Collateral Agent").

WITNESSETH:

WHEREAS, the Grantors are party to that certain Term Loan Guarantee and Collateral Agreement dated as of November 14, 2023 (as amended, amended and restated, supplemented, refinanced, replaced, extended or otherwise modified from time to time, the "Security Agreement") in favor of the Collateral Agent, pursuant to which the Grantors are required to execute and deliver this Patent Security Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meanings given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Patent Collateral. As security for the payment or performance when due (whether at stated maturity, by acceleration or otherwise), as the case may be, in full of the Secured Obligations, each Grantor hereby pledges to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, a security interest in all of such Grantor's right, title, and interest in or to any and all of the following Intellectual Property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the "Patent Collateral"), including:

- (a) all Patents issued or applied for in the United States, including those listed on Schedule I;
- (b) all provisionals, reissues, extensions, continuations, divisions, continuations-in-part, reexaminations or revisions thereof, and the inventions disclosed or claimed therein, including the right to make, use, import and/or sell the inventions disclosed or claimed therein;
- (c) all claims for, and rights to sue for, past or future infringements of any of the foregoing; and

- (d) all income, royalties, damages and payments now or hereafter due and payable with respect to any of the foregoing, including damages and payments for past or future infringement thereof.

SECTION 3. Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent pursuant to the Security Agreement and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Patent Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Recordation. This Patent Security Agreement has been executed and delivered by the Grantors for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. The Grantor authorizes and requests that the Commissioner of Patents record this Patent Security Agreement.


SECTION 5. Counterparts. This Patent Security Agreement may be executed in one or more counterparts, each of which shall constitute an original but all of which, when taken together, shall constitute but one contract. Delivery of an executed counterpart to this Patent Security Agreement by facsimile or other electronic transmission (e.g., "PDF" or "TIFF") shall be as effective as delivery of a manually signed original.

SECTION 6. Governing Law. THIS PATENT SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (EXCEPT FOR CONFLICTS OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION).

[Signature page follows]


IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

AMNEAL PHARMACEUTICALS LLC,
as Grantor

By:  _____

Name: Anastasios Konidaris
Title: Executive Vice
President and Chief
Financial Officer

IMPAX LABORATORIES, LLC,
as Grantor

By:  _____

Name: Anastasios Konidaris
Title: Executive Vice
President and Chief
Financial Officer

GEMINI LABORATORIES, LLC
as Grantor

By:  _____

Name: Anastasios Knoidaris
Title: Executive Vice
President and Chief
Financial Officer

Accepted and Agreed:

JPMORGAN CHASE BANK, N.A.,
as Collateral Agent

By: William R. Doolittle
Name: William R. Doolittle
Title: Executive Director

[Signature Page to Term Loan Patent Security Agreement]

PATENT
REEL: 065602 FRAME: 0478

SCHEDULE I
to
PATENT SECURITY AGREEMENT

PATENTS AND PATENT APPLICATIONS

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
1.	METHOD FOR THE PREPARATION OF CINACALCET AND INTERMEDIATES AND IMPURITIES THEREOF	United States of America	13/226061 06-Sep-2011	8575395 05-Nov-2013	AMNEAL PHARMACEUTICALS LLC (jointly owned with Megafine Pharma (P) Ltd.)
2.	METHOD FOR THE PREPARATION OF CINACALCET AND INTERMEDIATES AND IMPURITIES THEREOF	United States of America	14/052116 11-Oct-2013	8969623 03-Mar-2015	AMNEAL PHARMACEUTICALS LLC (jointly owned with Megafine Pharma (P) Ltd.)
3.	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING	United States of America	15/935894 26-Mar-2018	10434248 08-Oct-2019	AMNEAL PHARMACEUTICALS LLC
4.	KIT AND METHOD OF REDUCING HUMAN ERROR DURING IMPLANTED INFUSION PUMP REFILLING	United States of America	17/041886 25-Sep-2020		AMNEAL PHARMACEUTICALS LLC
5.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	United States of America	13/661800 26-Oct-2012	9180108 10-Nov-2015	AMNEAL PHARMACEUTICALS LLC
6.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	United States of America	14/935003 06-Nov-2015	9597304 21-Mar-2017	AMNEAL PHARMACEUTICALS LLC
7.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	United States of America	15/426136 07-Feb-2017	10076506 18-Sep-2018	AMNEAL PHARMACEUTICALS LLC
8.	BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME	United States of America	16/105615 20-Aug-2018	10420740 24-Sep-2019	AMNEAL PHARMACEUTICALS LLC
9.	BACLOFEN FORMULATIONS AND	United States of America	16/544128 19-Aug-2019	10813900 27-Oct-2020	AMNEAL PHARMACEUTICALS LLC

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
	METHODS FOR MAKING SAME				
10.	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	United States of America	16/524664 29-Jul-2019	10792262 06-Oct-2020	AMNEAL PHARMACEUTICALS LLC
11.	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	United States of America	18/122515 16-Mar-2023		AMNEAL PHARMACEUTICALS LLC
12.	STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES	United States of America	17/630297 26-Jan-2022	11654124 23-May-2023	AMNEAL PHARMACEUTICALS LLC
13.	IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS	United States of America	17/489343 29-Sep-2021	11491125 08-Nov-2022	AMNEAL PHARMACEUTICALS LLC
14.	IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS	United States of America	17/861844 11-Jul-2022		AMNEAL PHARMACEUTICALS LLC
15.	IMPROVED BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS	United States of America	PCT/US22/36975 13-Jul-2022		AMNEAL PHARMACEUTICALS LLC
16.	COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN	United States of America	17/525298 12-Nov-2021	11523984 13 Dec-2022	AMNEAL PHARMACEUTICALS LLC
17.	COMPOSITIONS AND METHODS OF ADMINISTERING BACLOFEN	United States of America	17/984001 9-Nov-2022		AMNEAL PHARMACEUTICALS LLC

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
18.	IMMUNO SUPPRESSIVE DOSAGE FORMS AND METHODS OF USE	United States of America	17/506748 21-Oct-2021		GEMINI LABORATORIES, LLC
19.	IMMUNO SUPPRESSIVE DOSAGE FORMS AND METHODS OF USE	United States of America	63/453187 20-Mar-2023		AMNEAL PHARMACEUTICALS LLC
20.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	12/599668 10-Nov-2009	8377474 19-Feb-2013	IMPAX LABORATORIES, LLC
21.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	13/711248 11-Dec-2012	8557283 15-Oct-2013	IMPAX LABORATORIES, LLC
22.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	13/900408 22-May-2013	9089607 28-Jul-2015	IMPAX LABORATORIES, LLC
23.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	14/030792 18-Sep-2013	9089608 28-Jul-2015	IMPAX LABORATORIES, LLC
24.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	14/030813 18-Sep-2013	9463246 11-Oct-2016	IMPAX LABORATORIES, LLC
25.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	14/958975 04-Dec-2015	9533046 03-Jan-2017	IMPAX LABORATORIES, LLC
26.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	15/382851 19-Dec-2016	9901640 27-Feb-2018	IMPAX LABORATORIES, LLC
27.	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF	United States of America	13/367230 06-Feb-2012	8454998 04-Jun-2013	IMPAX LABORATORIES, LLC

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
28.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	15/027654 06-Apr-2016	10098845 16-Oct-2018	IMPAX LABORATORIES, LLC
29.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	15/092086 06-Apr-2016	10292935 21-May-2019	IMPAX LABORATORIES, LLC
30.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	16/573634 17-Sep-2019	10987313 27-Apr-2021	IMPAX LABORATORIES, LLC
31.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	17/148320 13-Jan-2021	11357733 14-Jun-2022	IMPAX LABORATORIES, LLC
32.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	17/372434 10-Jul-2021	11622941 11-Apr-2023	IMPAX LABORATORIES, LLC
33.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	17/959681 04-Oct-2022	11666538 06-Jun-2023	IMPAX LABORATORIES, LLC
34.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR	United States of America	16/360936 21-Mar-2019	10688058 23-Jun-2020	IMPAX LABORATORIES, LLC

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
	ESTERS OF LEVODOPA AND USES THEREOF				
35.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	16/864323 01-May-2020	10973769 13-Apr-2021	IMPAX LABORATORIES, LLC
36.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	18/131715 06-April-2023		IMPAX LABORATORIES, LLC
37.	MUCO-ADHESIVE CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF	United States of America	17/959681 04-Oct-2022	1166538	AMNEAL PHARMACEUTICALS LLC
38.	Applicator for applying a liquid to a surface	United States of America	29475938 09-Dec-2013	D752287 22-Mar-2016	AMNEAL PHARMACEUTICALS LLC
39.	Inhalation device	United States of America	29520806 18-Mar-2015	D769439 18-Oct-2016	AMNEAL PHARMACEUTICALS LLC
40.	Inhalation device	United States of America	29520841 18-Mar-2015	D767114 2016-Sep-20	AMNEAL PHARMACEUTICALS LLC
41.	Refill Kit for Implantable Pump	United States of America	18/240,029 30-Aug-2023		AMNEAL PHARMACEUTICALS LLC
42.	SIMULTANEOUS USE OF IMAGING AND ENHANCED NEEDLES OR DEVICES TO IMPROVE SAFETY OF IMPLANTABLE PUMP REFILLS AND TROUBLESHOOTING	United States of America	16/637,114 06-Feb-2020		AMNEAL PHARMACEUTICALS LLC
43.	LEVODOPA DOSING REGIMEN	United States of America	17/558,337 21-Dec-2021		AMNEAL PHARMACEUTICALS LLC

	Patent Title	Country Name	Application Number Filing Date	Patent Number Grant Date	Owner
44.	LEVODOPA DOSING REGIMEN	United States of America	17/967,332 17-Oct-2022		AMNEAL PHARMACEUTICALS LLC